A comparative study of efficacy of artificial saliva and artificial saliva and ilaprazole combination therapy for the treatment of Burning mouth syndrome caused by Laryngopharyngeal reflux disease

Hallym University Medical Center-Kangnam0 个研究点目标入组 48 人开始时间: 待定最近更新: 2019年11月5日

适应症

试验速览

暂无简介。

•(1) Patients over 18 year
•(2) Laryngopharyngeal reflux disease patients who have RSI more than 13 and RFS more than 7
•(3) Patients with suspected burning mouth syndrome caused by laryngopharyngeal reflux disease

•(1) The highly sensitive person to proton pump inhibitor including ilaprazole
•(2) Those with the history of malignant tumor of the larynx
•(3) Those with need to take steroids or non-steroidal anti-inflammatory drugs including aspirin (more than 325mg/d), warfarin, coumarin during this clinical trial constantly
•(4) Those with observed a symptoms of vitamin B12 deficiency
•(5) Those who has undergone clonazepam therapy, hormone therapy, topical capsaicin treatment, topical lidocaine treatment, antidepressant, a-lipoic acid therapy
•(6) Those who has undergone surgery or treatment for gastroesophageal reflux disease
•(7) Those who has undergone gastric acid suppression surgery or gastro-duodenal surgery
•(8) Those who has undergone major surgery affecting gastric acid secretion except surgery such as appendectomy, cholecystectomy, hysterectomy
•(9) Psychiatric patient, alcohol addictor or those with the history of drug abuse
•(10) Pregnant and lactating women
•(11) Childbearing women (Menopausal women who are amenorrheic for at least 12 months are considered to be non-childbearing women.)
•(12) Those who participated in other clinical trial within 30 days before screening
•(13) Those who use another inhaler
•(14) Those with observed preneoplastic lesions or neoplastic lesions in pharynx or larynx
•(15) Those who are judged to be improper for this clinical trial

发起方

Hallym University Medical Center-Kangnam